Ascelia Pharma AB (publ) (ticker: ACE) today announced that the study where Orviglance® was compared against a gadolinium-based contrast agent has been accepted as an oral scientific presentation at t …
“We are pleased to achieve this impor-tant milestone to our exploration to help patients diagnosed with glioblastoma” explains Ulrich Kosciessa, photonamic GmbH & Co. KG’sCEO. “The accumu-
lation of the fluorescent photosensitizer protoporphyrin IX (PpIX) after systemic administration of 5-ALA proved high tumor selectivity.
Präziser operieren – mit Hilfe aus Pinneberg. Medizinforschung: Erleichterungen für Brustkrebspatientinnen greifbar nahe / Blaues Licht macht Tumorgewebe sichtbar.
“We are pleased having accomplished another milestone in our development for breastcancer program” explains Ulrich Kosciessa, photonamic GmbH & Co. KG’s CEO. “This study played a role in our strategic acquisition of the imaging technology in 2019...